Abstract
Research on Substance P (SP) has, until recently, focused on its role in pain and inflammation. However, a report that NK1 receptor antagonists have utility in the treatment of depression has stimulated research into the function of SP and the NK1 receptor in anxiety and depression. The distribution of SP and the NK1 receptor in brain areas implicated in anxiety and depression is initially reviewed. This is followed by evaluation of the preclinical data obtained for SP and NK1 receptor antagonists in behavioral models of depression as well as the phenotype of genetically modified animals lacking the genes encoding for the NK1 receptor or for SP. The weight of the evidence supports antidepressant and anxiolytic activity of NK1 receptor antagonists. However, many of the studies do not control for nonspecific effects of the compounds, and when enantiomers that lack activity at the NK1 receptor are included, the results, in some cases, suggest that blockade of NK1 receptors does not account for the observed behavioral activity. Finally, clinical studies in depressed patients assessing SP levels in plasma and cerebrospinal fluid as well as the effect of NK1 receptor antagonists are reviewed. The clinical studies are a mixture of positive, failed and negative studies on the antidepressant activity of NK1 receptor antagonists, not unlike the early clinical results obtained with selective serotonin reuptake inhibitors.
Keywords: substance p, nk receptor, depression, anxiety, clinical studies
Current Pharmaceutical Design
Title: Do Substance P and the NK1 Receptor have a Role in Depression and Anxiety?
Volume: 11 Issue: 12
Author(s): S. McLean
Affiliation:
Keywords: substance p, nk receptor, depression, anxiety, clinical studies
Abstract: Research on Substance P (SP) has, until recently, focused on its role in pain and inflammation. However, a report that NK1 receptor antagonists have utility in the treatment of depression has stimulated research into the function of SP and the NK1 receptor in anxiety and depression. The distribution of SP and the NK1 receptor in brain areas implicated in anxiety and depression is initially reviewed. This is followed by evaluation of the preclinical data obtained for SP and NK1 receptor antagonists in behavioral models of depression as well as the phenotype of genetically modified animals lacking the genes encoding for the NK1 receptor or for SP. The weight of the evidence supports antidepressant and anxiolytic activity of NK1 receptor antagonists. However, many of the studies do not control for nonspecific effects of the compounds, and when enantiomers that lack activity at the NK1 receptor are included, the results, in some cases, suggest that blockade of NK1 receptors does not account for the observed behavioral activity. Finally, clinical studies in depressed patients assessing SP levels in plasma and cerebrospinal fluid as well as the effect of NK1 receptor antagonists are reviewed. The clinical studies are a mixture of positive, failed and negative studies on the antidepressant activity of NK1 receptor antagonists, not unlike the early clinical results obtained with selective serotonin reuptake inhibitors.
Export Options
About this article
Cite this article as:
McLean S., Do Substance P and the NK1 Receptor have a Role in Depression and Anxiety?, Current Pharmaceutical Design 2005; 11 (12) . https://dx.doi.org/10.2174/1381612053764779
DOI https://dx.doi.org/10.2174/1381612053764779 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Psychoactive Effects of Antidepressants and their Association with Suicidality
Current Drug Safety Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Ghetto Poverty and Pollution in Egypt: A Deadly Threat for Western Countries Caused by New and Infectious Mutants. A Cultural, Social and Microbiological Synopsis
Inflammation & Allergy - Drug Targets (Discontinued) Current Developments in Therapeutic and Diagnostic Strategies for Q Fever: Glimpses of Patent Analysis
Recent Patents on Anti-Infective Drug Discovery New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry Effect of Valerian Extract on GABRB3 Gene MRNA Expression and Sedation in BALB/C Mice
Current Bioactive Compounds Withdrawal Notice: Mucoadhesive Microspheres: An Emerging Trends in Therapy of Diabetes Mellitus
Current Diabetes Reviews The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery An Overview on Inventions Related to Ginger Processing and Products for food and Pharmaceutical Applications
Recent Patents on Food, Nutrition & Agriculture TGR5 as a Therapeutic Target for Treating Obesity
Current Topics in Medicinal Chemistry Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Viral Reservoirs an Impediment to HAART: New Strategies to Eliminate HIV-1
Current Drug Targets - Infectious Disorders Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis
Current Topics in Medicinal Chemistry Current Treatment Options for Alzheimer’s Disease and Parkinson’s Disease Dementia
Current Neuropharmacology Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Endometriosis: The Role of Pharmacotherapy
Current Women`s Health Reviews Salvia divinorum: A Psychopharmacological Riddle and a Mind-Body Prospect
Current Drug Abuse Reviews Giardiasis: The Ever-Present Threat of a Neglected Disease
Infectious Disorders - Drug Targets Highly Selective Phosphodiesterase 4 Inhibitors for the Treatment of Allergic Skin Diseases and Psoriasis
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry